Journal: Life

Article Title: Effects of Physical Exercise and Motor Activity on Depression and Anxiety in Post-Mastectomy Pain Syndrome

doi: 10.3390/life14010077

Figure Lengend Snippet: Evaluation of the intensity of pain and BDNF, IL-17, IL1-β, ACTH, and cortisol in post-mastectomy pain (PMP) and non-post-mastectomy pain (non-PMP) groups at 3 and 6 months after surgery.

Article Snippet: The following kits were used: IL-17 (R&D System; Manufactured and Distributed by: USA R&D Systems, Inc. 614 McKinley Place NE, Minneapolis, MN 55413, USA, Catalog #: D1700); IL1-β (R&D System Catalog #: DLB50); BDNF (R&D System Catalog #: DBD00); ACTH (Novus biologicals; Novus Biologicals USA 10730 E. Briarwood Avenue Centennial, CO 80112, USA; NBP2-66401); and cortisol (Novus biologicals NBP3-18003).

Techniques:

Journal: Life

Article Title: Effects of Physical Exercise and Motor Activity on Depression and Anxiety in Post-Mastectomy Pain Syndrome

doi: 10.3390/life14010077

Figure Lengend Snippet: Evaluation of the intensity of pain, and biomarkers of BDNF, IL-17, IL1-β, ACTH, and cortisol in the DA-PM subgroup and non DA-PMP subgroup at 3 and 6 months after surgery.

Article Snippet: The following kits were used: IL-17 (R&D System; Manufactured and Distributed by: USA R&D Systems, Inc. 614 McKinley Place NE, Minneapolis, MN 55413, USA, Catalog #: D1700); IL1-β (R&D System Catalog #: DLB50); BDNF (R&D System Catalog #: DBD00); ACTH (Novus biologicals; Novus Biologicals USA 10730 E. Briarwood Avenue Centennial, CO 80112, USA; NBP2-66401); and cortisol (Novus biologicals NBP3-18003).

Techniques:

Journal: Life

Article Title: Effects of Physical Exercise and Motor Activity on Depression and Anxiety in Post-Mastectomy Pain Syndrome

doi: 10.3390/life14010077

Figure Lengend Snippet: Evaluation of the intensity of pain, and BDNF, IL-17, IL1-β, ACTH, and cortisol levels in the DA-PMP subgroup at 3 and 6 months after surgery, according to the physical activity score.

Article Snippet: The following kits were used: IL-17 (R&D System; Manufactured and Distributed by: USA R&D Systems, Inc. 614 McKinley Place NE, Minneapolis, MN 55413, USA, Catalog #: D1700); IL1-β (R&D System Catalog #: DLB50); BDNF (R&D System Catalog #: DBD00); ACTH (Novus biologicals; Novus Biologicals USA 10730 E. Briarwood Avenue Centennial, CO 80112, USA; NBP2-66401); and cortisol (Novus biologicals NBP3-18003).

Techniques: Activity Assay

Journal: Osteoarthritis and Cartilage Open

Article Title: Interleukin-6 receptor blockade improves bone healing following ischemic osteonecrosis in adolescent mice

doi: 10.1016/j.ocarto.2023.100386

Figure Lengend Snippet: The assessment of VEGF expression at 2 weeks post-surgery in vivo and under hypoxic chondrocyte culture in vitro . (A) VEGF immunohistochemistry (IHC) showed increased VEGF expression in the areas of revascularization in the necrotic epiphysis (EP) of the MR-16 group at 2 weeks compared to the saline group. VEGF expression was also increased in the articular cartilage (AC) of the MR16-1 group while it was unchanged in the growth plate cartilage (GP). Scale bar; 20 ​μm ​. (B) Human chondrocytes were pretreated with tocilizumab (1 ​μg/ml, 10 ​μg/ml) for 1 ​h, followed by IL1-β exposure under normoxia (20% oxygen) or hypoxia (1% oxygen) for 16 ​h. Expression levels of VEGF were significantly increased with tocilizumab pretreatment. The value of the non-treatment group (i.e., no treatment under normoxia) was set as 1.0. Kruskal-Wallis test followed by Mann-Whitney U test was used among 3 conditions with IL-1 treatment under hypoxia (IL-1, IL-1+1 ​μg/ml tocilizumab, and IL-1+10 ​μg/ml tocilizumab). Values were expressed by the mean ​± ​SD. Note that relative VEGF expression levels in hypoxia were higher compared to those in normoxia. ∗∗ p ​< ​0.01.

Article Snippet: Primary chondrocytes were isolated from human articular cartilage (IRB protocol Study ID: STU012011-114) [ ] and were pretreated with tocilizumab, a humanized anti-interleukin-6 receptor antibody as an analog of MR16-1, at either 1 ​μg/ml or 10 ​μg/ml concentration for 1 ​h, followed by interleukin-1β (recombinant human IL1-β; 12.5 ​ng/ml, R&D systems, Minneapolis, MN, USA) treatment to stimulate IL-6 [ ] under normoxia (20% oxygen) or hypoxia (1% oxygen) for 16 ​h.

Techniques: Expressing, In Vivo, In Vitro, Immunohistochemistry, Saline, MANN-WHITNEY

Journal: Mediators of Inflammation

Article Title: Epigenetic Regulation of Cytokine Production in Human Amnion and Villous Placenta

doi: 10.1155/2012/159709

Figure Lengend Snippet: Effect of AZA and TSA on cytokine production by villous explants in the presence or absence of LPS. The levels of cytokines were measured by ELISA. The y -axis shows the rate of mean IL1 β (a), TNF α (b), IL10 (c), and IL1Ra (d) production (as % basal control values), normalized against the wet tissue weight, and the x -axis shows the different treatment groups. Error bars represent 1 S.E.M. * P < 0.05, n = 3.

Article Snippet: Human IL1 β , TNF α , IL10, and IL1Ra ELISA kits were purchased from BD Bio Sciences.

Techniques: Enzyme-linked Immunosorbent Assay

Journal: Mediators of Inflammation

Article Title: Epigenetic Regulation of Cytokine Production in Human Amnion and Villous Placenta

doi: 10.1155/2012/159709

Figure Lengend Snippet: Effect of AZA and TSA on cytokine production by amnion explants in the presence or absence of LPS. The levels of cytokines were measured by ELISA. The y -axis shows the rate of mean IL1 β (a), TNF α (b), IL10 (c), and IL1Ra (d) production (as % basal control values), normalized against the wet tissue weight, and the x -axis shows the different treatment groups. Error bars represent 1 S.E.M.

Article Snippet: Human IL1 β , TNF α , IL10, and IL1Ra ELISA kits were purchased from BD Bio Sciences.

Techniques: Enzyme-linked Immunosorbent Assay